Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis
Background: Evidence is accumulating supporting a beneficial effect of vitamin D in multiple sclerosis (MS). Genome-wide association studies (GWAS) have shown significant associations between 25-hydroxyvitamin D (25(OH)D) and single nucleotide polymorphisms (SNPs) in key genes in the vitamin D metab...
Saved in:
| Published in: | Multiple sclerosis Vol. 21; no. 11; pp. 1414 - 1422 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London, England
SAGE Publications
01.10.2015
Sage Publications Ltd |
| Subjects: | |
| ISSN: | 1352-4585, 1477-0970, 1477-0970 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background:
Evidence is accumulating supporting a beneficial effect of vitamin D in multiple sclerosis (MS). Genome-wide association studies (GWAS) have shown significant associations between 25-hydroxyvitamin D (25(OH)D) and single nucleotide polymorphisms (SNPs) in key genes in the vitamin D metabolism.
Objective:
To examine the association between 25(OH)D and six GWAS SNPs and environmental factors in 1497 MS patients.
Methods:
Blood samples and lifestyle questionnaires were collected between 2009 and 2012. Genotyping of GC-, CYP2R1- and NADSYN1-SNPs was performed by TaqMan allelic discrimination (Life Technologies).
Results:
We found significant associations between 25(OH)D and SNPs in GC (rs7041, p = 0.01 and rs2282679, p = 0.03) and CYP2R1 (rs10741657, p =1.8 × 10−4). Season of blood sampling (p = 2.8 × 10−31), sex (p = 1.9 × 10−5), BMI (p = 2.3 × 10−5), vitamin supplements (p = 7.0 × 10−22), and fish intake (p = 0.02) also had significant effects on 25(OH)D.
Conclusion:
In this cross-sectional study, we found significant effects of environmental factors and SNPs in GC and CYP2R1 on 25(OH)D in MS patients. Since 25(OH)D might have protective effects in MS, and vitamin D supply is a modifiable factor, it may be important to include this in the MS treatment regimen. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ISSN: | 1352-4585 1477-0970 1477-0970 |
| DOI: | 10.1177/1352458514563590 |